[Bioundgrd] Fwd: 2003-2004 EMBS-BMES Distinguished Lecture Series--February 17th

[Janice Chang]

>
>Dear colleagues and friends,
>
>The Boston chapter of the Institute of Electrical and Electronics Engineers
>         (IEEE)-Engineering in Medicine and Biology Society (EMBS)
>                                  &
>               the MIT Biomedical Engineering Society (BMES)
>                           proudly present:
>
>        *** The 2003-2004 EMBS-BMES Distinguished Lecture Series ***
>
>We invite you to join us for our new monthly lecture series in which 
>we explore
>recent developments and stimulating topics in the expanding field of 
>biomedical
>engineering.  In the spring, speakers from both academia and 
>industry will introduce such
>subjects as genes, genomics, proteomics, and systems biology.
>
>Our sixth lecture will be:
>
>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
>The Drug Discovery Process: An Industrial Perspective
>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
>
>W. Stephen Faraci, Senior Director, Discovery Technology Center
>Pfizer Global R & D, Cambridge, MA
>
>Tuesday, February 17, 2004
>7PM (Refreshments at 6:30PM)
>MIT Building 66, 25 Ames Street, Room 66-110
>(For directions to MIT, please visit http://whereis.mit.edu)
>
>* This event is free and open to the public.*
>
>************************************************************************
>
>ABSTRACT:
>
>The drug discovery process is a long and costly process, taking over 
>15 years from idea generation to approved drug and costing almost 1 
>billion dollars. There are many reasons for this, including 
>long-term safety studies, complex regulatory issues and the high 
>level of attrition of drugs entering preclinical and clinical 
>development. This talk will focus on the drug discovery process, 
>from target identification to IND filing to NDA submission. New 
>technologies that can aid in this process and help reduce the 
>attrition currently observed in the industry will be discussed.
>
>SPEAKER BACKGROUND:
>
>W. Stephen Faraci, PhD, is Senior Director and Head, Biology as well 
>as Interim Site Head at the Discovery Technology Center (DTC) in 
>Cambridge, Massachusetts—which is a part of Pfizer’s Global Research 
>and Development division. Steve received his PhD in Chemistry from 
>Wesleyan University in 1986 and did postdoctoral research with 
>Professor Christopher Walsh at MIT from 1986 – 1988. He joined 
>Pfizer Central Research in Groton, CT in 1988 as a Research 
>Scientist in the New Leads Department, which was pioneering the use 
>of high throughput screening. In 1999, he relocated to the DTC in 
>Cambridge, MA as Pfizer opened a new site in the Boston area. The 
>goal of the DTC is to improve the efficiency of the drug discovery 
>paradigm. This goal is being approached through the integration of 
>new technologies to enable high speed screening of genome-derived 
>targets for new drug candidates and the evaluation of a new 
>discovery paradigm based on gene families as well as strategies to 
>rapidly synthesize compounds using parallel methodologies in order 
>to profile these leads across a wide-range of biological endpoints.
>
>************************************************************************
>
>If you have any questions, please do not hesitate to contact us.  We look
>forward to seeing you!
>
>
>Best Regards,
>
>Mandy Yeung					Alexis DeSieno
>VP of Special Programs			President
>BMES,MIT Chapter				BMES, MIT Chapter
>mandyy at mit.edu				alexisd at mit.edu
-------------- next part --------------
An HTML attachment was scrubbed...
URL: http://mailman.mit.edu/pipermail/bioundgrd/attachments/20040210/25f842c4/attachment.htm